Роль тау-белка в этиопатогенезе преэклампсии как протеинопатии второй половины беременности

1. Борис Д.А., Шмаков Р.Г. Преэклампсия: современные концепции патогенеза. Акушерство и гинекология. 2022; 12: 12-7. https://dx.doi.org/10.18565/aig.2022.213
2. Gestational hypertension and preeclampsia. ACOG Practice Bulletin, Number 222. Obstet. Gynecol. 2020; 135(6): e237-e260. https://dx.doi.org/10.1097/AOG.0000000000003891
3. Федеральная служба государственной статистики (Росстат). Здравоохранение в России 2025. Статистический сборник. М.: Росстат; 2025. 149 с.
4. Medegan Fagla B., Buhimschi I.A. Protein misfolding in pregnancy: current insights, potential mechanisms, and implications for the pathogenesis of preeclampsia. Molecules. 2024; 29(3): 610. https://dx.doi.org/10.3390/molecules29030610
5. Amabebe E., Huang Z., Jash S., Krishnan B., Cheng S., Nakashima A. et al. Novel role of Pin1-Cis P-Tau-ApoE axis in the pathogenesis of preeclampsia and its connection with dementia. Biomedicines. 2024; 13(1): 29. https://dx.doi.org/10.3390/biomedicines13010029
6. Fiock K.L., Smalley M.E., Crary J.F., Pasca A.M., Hefti M.M. Increased tau expression correlates with neuronal maturation in the developing human cerebral cortex. eNeuro. 2020; 7(3): ENEURO.0058-20.2020. https://dx.doi.org/10.1523/ENEURO.0058-20.2020
7. Canepa E., Fossati S. Impact of tau on neurovascular pathology in Alzheimer's disease. Front. Neurol. 2021; 11: 573324. https://dx.doi.org/10.3389/fneur.2020.573324
8. Jash S., Banerjee S., Cheng S., Wang B., Qiu C., Kondo A. et al. Cis P-Tau is a central circulating and placental etiologic driver and therapeutic target of preeclampsia. Nat. Commun. 2023; 14(1): 5414. https://dx.doi.org/10.1038/s41467-023-41144-6
9. Qiu C., Li Z., Leigh D.A., Duan B., Stucky J.E., Kim N. et al. The role of the Pin1-cis P-tau axis in the development and treatment of vascular contribution to cognitive impairment and dementia and preeclampsia. Front. Cell Dev. Biol. 2024; 12: 1343962. https://dx.doi.org/10.3389/fcell.2024.1343962
10. Michalicova A., Majerova P., Kovac A. Tau protein and its role in blood-brain barrier dysfunction. Front. Mol. Neurosci. 2020; 13: 570045. https://dx.doi.org/10.3389/fnmol.2020.570045
11. Shen X., Li H., Zhang B., Li Y., Zhu Z. Tau-targeted therapeutic strategies: mechanistic targets, clinical pipelines, and analysis of failures. Cells. 2025; 14(19): 1506. https://dx.doi.org/10.3390/cells14191506
12. Combs B., Mueller R.L., Morfini G., Brady S.T., Kanaan N.M. Tau and axonal transport misregulation in tauopathies. Adv. Exp. Med. Biol. 2019; 1184: 81-95. https://dx.doi.org/10.1007/978-981-32-9358-8_7
13. Chinnathambi S., Rangappa N. SUMO inhibits Tau aggregation in Alzheimer's disease. Adv. Protein Chem. Struct. Biol. 2025; 147: 355-74. https://dx.doi.org/10.1016/bs.apcsb.2025.02.001
14. Wang R., Lu K.P., Zhou X.Z. Function and regulation of cis P-tau in the pathogenesis and treatment of conventional and nonconventional tauopathies. J. Neurochem. 2023; 166: 904-14. https://dx.doi.org/10.1111/jnc.15909
15. Wang L., Zhou Y., Chen D., Lee T.H. Peptidyl-prolyl cis/trans isomerase Pin1 and Alzheimer's disease. Front. Cell Dev. Biol. 2020; 8: 355. https://dx.doi.org/10.3389/fcell.2020.00355
16. Jeong J., Usman M., Li Y., Zhou X.Z., Lu K.P. Pin1-catalyzed conformation changes regulate protein ubiquitination and degradation. Cells. 2024; 13(9): 731. https://dx.doi.org/10.3390/cells13090731
17. Xia Y., Prokop S., Giasson B.I. “Don’t Phos Over Tau”: Recent developments in clinical biomarkers and therapies targeting tau phosphorylation in Alzheimer’s disease and other tauopathies. Mol. Neurodegener. 2021; 16: 37. https://dx.doi.org/10.1186/s13024-021-00460-5
18. Cline E.N., Bicca M.A., Viola K.L., Klein W.L. The amyloid-β oligomer hypothesis: beginning of the third decade. Journal of Alzheimer’s Disease. 2018; 64(s1): S567-S610. https://dx.doi.org/10.3233/JAD-179941
19. Koike H., Iguchi Y., Sahashi K., Katsuno M. Significance of oligomeric and fibrillar species in amyloidosis: insights into pathophysiology and treatment. Molecules. 2021; 26(16): 5091. https://dx.doi.org/10.3390/molecules26165091
20. Plácido A.I., Pereira C.M.F., Correira S.C., Carvalho C., Oliveira C.R., Moreira P.I. Phosphatase 2A inhibition affects endoplasmic reticulum and mitochondria homeostasis via cytoskeletal alterations in brain endothelial cells. Mol. Neurobiol. 2017; 54(1): 154-68. https://dx.doi.org/10.1007/s12035-015-9640-1
21. Niewiadomska G., Niewiadomski W., Steczkowska M., Gasiorowska A. Tau oligomers neurotoxicity. Life (Basel). 2021; 11(1): 28. https://dx.doi.org/10.3390/life11010028
22. Chiti F., Dobson C.M. Protein misfolding, amyloid formation, and human disease: a summary of progress over the last decade. Annu. Rev. Biochem. 2017; 86(1): 27-68. https://dx.doi.org/10.1146/annurev-biochem-061516-045115
23. Guo T., Noble W., Hanger D.P. Roles of tau protein in health and disease. Acta. Neuropathol. 2017; 133(5): 665-704. https://dx.doi.org/10.1007/s00401-017-1707-9
24. Lu K.P., Zhou X.Z. Pin1-catalyzed conformational regulation after phosphorylation: a distinct checkpoint in cell signaling and drug discovery. Sci. Signal. 2024; 17(841) eadi8743. https://dx.doi.org/10.1126/scisignal.adi8743
25. Lederer W., Dominguez C.A., Popovscaia M., Putz G., Humpel C. Cerebrospinal fluid levels of tau and phospho-tau-181 proteins during pregnancy. Pregnancy Hypertens. 2016; 6(4): 384-7. https://dx.doi.org/10.1016/j.preghy.2016.08.243
26. Bergman L., Zetterberg H., Kaihola H., Hagberg H., Blennow K., Åkerud H. Blood-based cerebral biomarkers in preeclampsia: Plasma concentrations of NfL, tau, S100B and NSE during pregnancy in women who later develop preeclampsia - A nested case control study. PLoS One. 2018; 13(5): e0196025. https://dx.doi.org/10.1371/journal.pone.0196025
27. Sharma S. Autophagy-based diagnosis of pregnancy hypertension and pre-eclampsia. Am. J. Pathol. 2018; 188(11): 2457-60. https://dx.doi.org/110.1016/j.ajpath.2018.09.001
28. Aoki A., Nakashima A., Kusabiraki T., Ono Y., Yoshino O., Muto M. et al. Trophoblast-specific conditional Atg7 knockout mice develop gestational hypertension. Am. J. Pathol. 2018; 188(11): 2474-86. https://dx.doi.org/10.1016/j.ajpath.2018.07.021
29. Qiu C., Albayram O., Kondo A., Wang B., Kim N., Arai K. et al. Cis P-tau underlies vascular contribution to cognitive impairment and dementia and can be effectively targeted by immunotherapy in mice. Sci. Transl. Med. 2021; 13(596): eaaz7615. https://dx.doi.org/10.1126/scitranslmed.aaz7615
30. Huebner H., Knoerr B., Betzler A., Hartner A., Kehl S., Baier F. et al. Detyrosinatedtubulin is decreased in fetal vessels of preeclampsia placentas. Placenta. 2018; 62: 58-65. https://dx.doi.org/10.1016/j.placenta.2017.12.019
31. Wu Y.C., Bogale T.A., Koistinaho J., Pizzi M., Rolova T., Bellucci A. The contribution of β-amyloid, Tau and α-synuclein to blood-brain barrier damage in neurodegenerative disorders. Acta Neuropathol. 2024; 147(1): 39. https://dx.doi.org/10.1007/s00401-024-02696-z
32. Majerova P., Michalicova A., Cente M., Hanes J., Vegh J., Kittel A. et al. Trafficking of immune cells across the blood-brain barrier is modulated by neurofibrillary pathology in tauopathies. PLoS One. 2019; 14(5): e0217216. https://dx.doi.org/10.1371/journal.pone.0217216
33. Escudero C., Kupka E., Ibañez B., Sandoval H., Troncoso F., Wikström A.K. et al. Brain vascular dysfunction in mothers and their children exposed to preeclampsia. Hypertension. 2022; 79: 242-56. https://dx.doi.org/10.1161/HYPERTENSIONAHA.122.19408
34. Bergman L., Hastie R., Bokstrom-Rees E., Zetterberg H., Blennow K., Schell S. et al. Cerebral biomarkers in neurologic complications of preeclampsia. Am. J. Obstet. Gynecol. 2022; 227(2): 298e1-10. https://dx.doi.org/10.1016/j.ajog.2022.02.036
35. Kaur S., Darden C.J., Adegbola G.M., Warrington J.P. History of hypertensive disorders of pregnancy and risk of Alzheimer's disease and vascular dementia. Front. Neuroendocrinol. 2025; 78: 101198. https://dx.doi.org/10.1016/j.yfrne.2025.101198
36. Huang Z., Cheng S., Jash S., Fierce J., Agudelo A., Higashiyama T. et al. Exploiting sweet relief for preeclampsia by targeting autophagy-lysosomal machinery and proteinopathy. Exp. Mol. Med. 2024; 56(5): 1206-20. https://dx.doi.org/10.1038/s12276-024-01234-x
37. Сидорова И.С., Никитина Н.А. Обоснование современной концепции развития преэклампсии. Акушерство и гинекология. 2019; 4: 26-33. https://dx.doi.org/10.18565/aig.2019.4.26-33
38. Zhou P., Wang J., Wang J., Liu X. When autophagy meets placenta development and pregnancy complications. Front. Cell Dev. Biol. 2024; 12: 1327167. https://dx.doi.org/10.3389/fcell.2024.1327167
39. Ribeiro V.R., Romao-Veiga M., Nunes P.R., Peracoli J.C., Peracoli M.T.S. Increase of autophagy marker p62 in the placenta from pregnant women with preeclampsia. Hum. Immunol. 2022; 83(10022): 447-52. https://dx.doi.org/10.1016/j.humimm.2022.02.005
40. Zheng W., Zhang Y., Xu P., Wang Z., Shao X., Chen C. et al. TFEB safeguards trophoblast syncytialization in humans and mice. Proc. Natl. Acad. Sci. USA. 2024; 121(28): e2404062121. https://dx.doi.org/10.1073/pnas.2404062121
41. Nakashima A., Cheng S.B., Ikawa M., Yoshimori T., Huber W.J., Menon R. et al. Evidence for lysosomal biogenesis proteome defect and impaired autophagy in preeclampsia. Autophagy. 2020; 16(10): 1771-85. https://dx.doi.org/10.1080/15548627.2019.1707494
42. Nakashima A., Tsuda S., Kusabiraki T., Aoki A., Ushijima A., Shima T. et al. Current understanding of autophagy in pregnancy. Int. J. Mol. Sci. 2019; 20(9): 2342. https://dx.doi.org/10.3390/ijms20092342
43. Cheng S., Banerjee S., Daiello L.A., Nakashima A., Jash S., Huang Z. et al. Novel blood test for early biomarkers of preeclampsia and Alzheimer’s disease. Sci. Rep. 2021; 11: 15934. https://dx.doi.org/10.1038/s41598-021-95611-5
44. Janelidze S., Mattsson N., Palmqvist S., Smith R., Beach T.G., Serrano G.E. et al. Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia. Nat. Med. 2020; 26: 379-86. https://dx.doi.org/10.1038/s41591-020-0755-1
45. Palmqvist S., Janelidze S., Quiroz Y.T., Zetterberg H., Lopera F., Stomrud E. et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2020; 324(8): 772-81. https://dx.doi.org/10.1001/jama.2020.12134
46. Fagiani F., Govoni S., Racchi M., Lanni C. The Peptidyl-prolyl isomerase Pin1 in neuronal signaling: from neurodevelopment to neurodegeneration. Mol. Neurobiol. 2021; 58(3): 1062-73. https://dx.doi.org/10.1007/s12035-020-02179-8
47. Sedov I., Khaibrakhmanova D. Molecular mechanisms of inhibition of protein amyloid fibril formation: evidence and perspectives based on kinetic models. Int. J. Mol. Sci. 2022; 23(21): 13428. https://dx.doi.org/10.3390/ijms232113428
48. Al-Hilaly Y.K., Rickard J.E., Simpson M., Storey J.M.D., Harrington C.R., Wischik C.M. et al. A key region of Tau that is able to drive assembly and modulate inhibition by Hydromethylthionine. J. Mol. Biol. 2025; 437(17): 169231. https://dx.doi.org/10.1016/j.jmb.2025.169231
49. Сидорова И.С., Манагадзе И.Д. Современные представления о преэклампсии с учетом роли нейронспецифических белков головного мозга плода. Акушерство и гинекология. 2025; 1: 5-11. https://dx.doi.org/10.18565/aig.2024.221
50. Сидорова И.С., Манагадзе И.Д. Сущность преэклампсии и возможности ее прекращения. Акушерство и гинекология. 2026; 1: 5-11. https://dx.doi.org/10.18565/aig.2025.223
51. Сидорова И.С., Манагадзе И.Д. Современная концепция развития преэклампсии: новые данные. Акушерство и гинекология. 2025; 2: 5-13. https://dx.doi.org/10.18565/aig.2024.272

Поступила 28.01.2026

Принята в печать 18.05.2026